5-isopropyl-2-methoxybenzoic acid | 68014-67-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-isopropyl-2-methoxybenzoic acid
• 英文别名: 5-isopropyl-2-methoxy-benzoic acid；2-Methoxy-5-isopropylbenzoesaeure；2-methoxy-5-propan-2-ylbenzoic acid
• CAS: 68014-67-5
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: CFFMTKRMOKYESO-UHFFFAOYSA-N

物化性质

• 熔点：
  60-61 °C
• 沸点：
  140-142 °C(Press: 2 Torr)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-isopropyl-2-methoxybenzoic acid 、 二乙胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N,N-Diethyl-5-isopropyl-2-methoxybenzamide
  参考文献：
  名称：

  Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency

  摘要：

  Inhibitors of the chaperone Hsp90 are potentially useful as chemotherapeutic agents in cancer. This paper describes an application of fragment screening to Hsp90 using a combination of NMR and high throughput X-ray crystallography. The screening identified an aminopyrimidine with affinity in the high micromolar range and subsequent structure-based design allowed its optimization into a low nanomolar series with good ligand efficiency. A phenolic chemotype was also identified in fragment screening and was found to bind with affinity close to 1 mM. This fragment was optimized using structure based design into a resorcinol lead which has subnanomolar affinity for Hsp90, excellent cell potency, and good ligand efficiency. This fragment to lead campaign improved affinity for Hsp90 by over 1,000,000-fold with the addition of only six heavy atoms. The companion paper (DOI: 10.1021/jm100060b) describes how the resorcinol lead was optimized into a compound that is now in clinical trials for the treatment of cancer.

  DOI：

  10.1021/jm100059d
• 作为产物：
  描述：

  5-异丙基-2-甲氧基苯甲醛 在 sodium chlorite 、 氨基磺酸 作用下， 以 水 、 丙酮 为溶剂， 反应 12.0h， 生成 5-isopropyl-2-methoxybenzoic acid
  参考文献：
  名称：

  [EN] 1, 2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS
  [FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DES RÉCEPTEURS CANNABINOÏDES

  摘要：

  公开号：

  WO2010054024A3

文献信息

• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070099874A1

  公开（公告）日：2007-05-03

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及用于治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖化蛋白诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗由平滑肌增殖所特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090023789A1

  公开（公告）日：2009-01-22

  The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有异噻唑烷基的化合物，其化学式为（I），其中R1、R2、R3、R4和L如规范中所定义，包括这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• DIHYDROXYPHENYL ISOINDOLYLMETHANONES
  申请人：Chessari Gianni

  公开号：US20070259886A1

  公开（公告）日：2007-11-08

  Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.

  具有公式(I)的化合物，特别是VIIa亚属的化合物，被披露为热休克蛋白Hsp90的抑制剂或调节剂。因此，它们可用于治疗癌症，特别是淋巴或骨髓系的造血肿瘤、前列腺癌、肺癌、胃肠间质瘤、乳腺癌和黑色素瘤。
• Pharmaceutical Compounds
  申请人：Chessari Gianni

  公开号：US20080306054A1

  公开（公告）日：2008-12-11

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R 1 is hydroxy or hydrogen; R 2 is hydroxy; methoxy or hydrogen; provided that at least one of R 1 and R 2 is hydroxy; R 3 is selected from hydrogen; halogen; cyano; C 1-5 hydrocarbyl and C 1-5 hydrocarbyloxy; wherein the C 1-5 hydrocarbyl and C 1-5 hydrocarbyloxy moieties are each optionally substituted by one or more substituents selected from hydroxy, halogen, C 1-2 alkoxy, amino, mono- and di-C 1-2 alkylamino, and aryl and heteroaryl groups of 5 to 12 ring members; R 4 is selected from hydrogen; a group —(O) n —R 7 where n is 0 or 1 and R 7 is an acyclic C 1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and mono- or di-C 1-5 hydrocarbyl-amino, wherein the acyclic C 1-5 hydrocarbyl group and the mono and di-C 1-5 hydrocarbylamino moieties in each instance are optionally substituted by one or more substituents selected from hydroxy, halogen, C 1-2 alkoxy, amino, mono- and di-C 1-2 alkylamino, and aryl and heteroaryl groups of 5 to 12 ring members; or R 3 and R 4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and R 5 and R 6 are as defined in the claims.

  本发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式子（I）或其盐，互变异构体，溶剂合物和N-氧化物；其中，R1是羟基或氢基；R2是羟基，甲氧基或氢基；只要R1和R2中至少有一个是羟基；R3选自氢基，卤素，氰基，C1-5烃基和C1-5烃氧基；其中C1-5烃基和C1-5烃氧基基团均可选择地被一个或多个取代基所取代，所述取代基选自羟基，卤素，C1-2烷氧基，氨基，单烷基和双C1-2烷基氨基以及5至12个环成员的芳基和杂环芳基；R4选自氢基，—（O）n—R7基团，其中n为0或1，R7是一个无环C1-5烃基基团或一个具有3至7个环成员的单环碳环或杂环基团；卤素，氰基，羟基，氨基和单烷基或双C1-5烃基氨基，其中在每种情况下，无环C1-5烃基基团和单烷基和双C1-5烃基氨基基团可选择地被一个或多个取代基所取代，所述取代基选自羟基，卤素，C1-2烷氧基，氨基，单烷基和双C1-2烷基氨基以及5至12个环成员的芳基和杂环芳基；或R3和R4共同形成一个具有5至7个环成员的单环碳环或杂环基团；R5和R6如权利要求所定义。
• Compounds as cannabinoid receptor ligands
  申请人：Abbott Laboratories

  公开号：US07872033B2

  公开（公告）日：2011-01-18

  The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及公式（I）中含有异噻唑烷酮的化合物，其中R1、R2、R3、R4和L如规范中所定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。